Recombinant & Conjugate Vaccine Development

Conjugate vaccines rely on bioconjugation to enhance the immune response against a poorly immunogenic small molecule. Conjugate vaccines are a significant step forward in immunization technology, particularly for combating bacterial pathogens that have a polysaccharide capsule. These vaccines have made substantial public health contributions, drastically reducing the incidence of diseases such as bacterial meningitis and pneumonia caused by pathogens like Haemophilus influenzae type b (Hib), pneumococcus, and various serogroups of meningococcus. Future advancements could lead to more effective conjugate vaccines against a broader range of pathogens.

Peptide conjugate vaccines require specialized expertise and technologies in order to achieve its next target inflection point. Abzena’s conjugation team of experts are able to link custom peptides and polysaccharides to carrier proteins to generate novel vaccine conjugates. To find out more. Download our case study today by clicking the link below.

Immunogenicity assessments play a critical role in the development of recombinant and conjugate vaccines. Unintended immune responses can severely compromise the safety and efficacy of treatments. EpiScreen® 2.0 is our innovative solution to the challenges and risk posed. EpiScreen® 2.0 offers a high sensitivity and a multi-parametric, data-rich platform that streamlines vaccine candidate selection.

At an integrated CDMO, EpiScreen® 2.0 is underpinned by our strong bioassay and analytics capabilities. Through our approach, we are able to ensure that your vaccine is successfully delivered to IND for clinical trial evaluation.